Insulet (PODD) Stock Forecast, Price Target & Predictions
PODD Stock Forecast
Insulet stock forecast is as follows: an average price target of $274.00 (represents a 5.34% upside from PODD’s last price of $260.12) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
PODD Price Target
The average price target for Insulet (PODD) is $274.00 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $350.00 to $200.00. This represents a potential 5.34% upside from PODD's last price of $260.12.
PODD Analyst Ratings
According to 17 Wall Street analysts, Insulet's rating consensus is 'Buy'. The analyst rating breakdown for PODD stock is 0 'Strong Buy' (0.00%), 15 'Buy' (88.24%), 2 'Hold' (11.76%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Insulet Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 08, 2024 | Marie Thibault | BTIG | $270.00 | $268.96 | 0.39% | 3.80% |
| Nov 05, 2024 | Lee Hambright | Bernstein | $300.00 | $241.32 | 24.32% | 15.33% |
| Oct 14, 2024 | Jayson Bedford | Raymond James | $260.00 | $231.61 | 12.26% | -0.05% |
| Sep 17, 2024 | Matt O'Brien | Piper Sandler | $285.00 | $233.89 | 21.85% | 9.56% |
| Aug 27, 2024 | Matt O'Brien | Piper Sandler | $230.00 | $193.51 | 18.85% | -11.58% |
| Aug 27, 2024 | Steven Lichtman | Oppenheimer | $233.00 | $193.54 | 20.39% | -10.43% |
| Aug 27, 2024 | Matthew Taylor | Jefferies | $260.00 | $193.54 | 34.34% | -0.05% |
| Aug 09, 2024 | Marie Thibault | BTIG | $250.00 | $199.79 | 25.13% | -3.89% |
| May 13, 2024 | Matt Miksic | Barclays | $200.00 | $165.90 | 20.55% | -23.11% |
| May 07, 2024 | Mike Polark | Wolfe Research | $200.00 | $176.40 | 13.38% | -23.11% |
The latest Insulet stock forecast, released on Nov 08, 2024 by Marie Thibault from BTIG, set a price target of $270.00, which represents a 0.39% increase from the stock price at the time of the forecast ($268.96), and a 3.80% increase from PODD last price ($260.12).
Insulet Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 7 | 11 |
| Avg Price Target | $285.00 | $262.57 | $246.73 |
| Last Closing Price | $260.12 | $260.12 | $260.12 |
| Upside/Downside | 9.56% | 0.94% | -5.15% |
In the current month, the average price target of Insulet stock is $285.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 9.56% increase as opposed to Insulet's last price of $260.12. This month's average price target is up 8.54% compared to last quarter, and up 15.51% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 05, 2024 | Bernstein | - | Outperform | Initialise |
| Oct 14, 2024 | William Blair | Buy | Buy | Hold |
| Oct 14, 2024 | Raymond James | Outperform | Outperform | Hold |
| Sep 17, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 17, 2024 | UBS | Buy | Buy | Hold |
| Sep 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 27, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 27, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
Insulet's last stock rating was published by Bernstein on Nov 05, 2024. The company Initialise its PODD rating from "null" to "Outperform".
Insulet Financial Forecast
Insulet Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $432.70M | $396.50M | $358.10M | $369.70M | $340.80M | $299.40M | $295.40M | $307.70M | $275.60M | $263.20M | $252.30M | $246.10M | $234.00M | $226.30M | $198.00M | $209.39M | $192.12M |
| Avg Forecast | $790.86M | $729.96M | $679.61M | $641.08M | $681.92M | $626.42M | $578.89M | $542.95M | $581.61M | $519.51M | $488.00M | $424.05M | $461.26M | $414.32M | $385.26M | $330.91M | $332.45M | $312.11M | $291.45M | $288.02M | $299.33M | $272.62M | $258.88M | $247.53M | $232.90M | $221.72M | $212.41M | $189.44M | $199.51M | $179.49M |
| High Forecast | $803.69M | $741.81M | $690.64M | $651.48M | $692.99M | $636.58M | $588.28M | $553.47M | $588.26M | $519.87M | $495.92M | $424.05M | $467.11M | $419.27M | $391.51M | $336.28M | $337.84M | $312.11M | $291.45M | $288.02M | $299.33M | $272.62M | $258.88M | $247.53M | $232.90M | $221.72M | $212.41M | $189.44M | $199.51M | $179.49M |
| Low Forecast | $773.10M | $713.57M | $664.35M | $626.68M | $666.61M | $612.35M | $565.89M | $530.28M | $568.62M | $519.16M | $477.04M | $424.05M | $456.38M | $406.12M | $376.61M | $323.48M | $324.98M | $312.11M | $291.45M | $288.02M | $299.33M | $272.62M | $258.88M | $247.53M | $232.90M | $221.72M | $212.41M | $189.44M | $199.51M | $179.49M |
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 13 | 7 | 7 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.03% | 1.08% | 1.11% | 1.09% | 1.03% | 1.03% | 1.03% | 1.01% | 1.02% | 1.02% | 1.06% | 1.06% | 1.07% | 1.05% | 1.05% | 1.07% |
Insulet's average Quarter revenue forecast for Dec 23 based on 9 analysts is $461.26M, with a low forecast of $456.38M, and a high forecast of $467.11M. PODD's average Quarter revenue forecast represents a 6.60% increase compared to the company's last Quarter revenue of $432.70M (Sep 23).
Insulet EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 13 | 7 | 7 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.50M | $31.10M | $27.50M | $25.00M | $1.10M | $-27.80M | $38.20M | $62.60M | $45.20M | $2.40M | $25.90M | $19.20M | $35.50M | $38.40M | $17.20M | $26.14M | $17.56M |
| Avg Forecast | $99.31M | $91.67M | $85.34M | $80.50M | $85.63M | $78.66M | $72.69M | $68.18M | $73.04M | $65.24M | $61.28M | $61.46M | $57.92M | $52.03M | $48.38M | $55.87M | $47.34M | $24.90M | $23.25M | $50.79M | $23.88M | $21.75M | $20.65M | $46.62M | $18.58M | $20.00M | $16.94M | $15.11M | $15.92M | $14.32M |
| High Forecast | $100.92M | $93.15M | $86.73M | $81.81M | $87.02M | $79.94M | $73.87M | $69.50M | $73.87M | $65.28M | $62.28M | $73.75M | $58.66M | $52.65M | $49.16M | $67.04M | $56.81M | $24.90M | $23.25M | $60.95M | $23.88M | $21.75M | $20.65M | $55.94M | $18.58M | $24.00M | $16.94M | $15.11M | $15.92M | $14.32M |
| Low Forecast | $97.08M | $89.61M | $83.43M | $78.70M | $83.71M | $76.90M | $71.06M | $66.59M | $71.40M | $65.19M | $59.91M | $49.17M | $57.31M | $51.00M | $47.29M | $44.70M | $37.87M | $24.90M | $23.25M | $40.63M | $23.88M | $21.75M | $20.65M | $37.30M | $18.58M | $16.00M | $16.94M | $15.11M | $15.92M | $14.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 0.64% | 0.49% | 0.53% | 0.04% | -1.20% | 0.75% | 2.62% | 2.08% | 0.12% | 0.56% | 1.03% | 1.77% | 2.27% | 1.14% | 1.64% | 1.23% |
9 analysts predict PODD's average Quarter EBITDA for Dec 23 to be $57.92M, with a high of $58.66M and a low of $57.31M. This is 4.37% upper than Insulet's previous annual EBITDA (Sep 23) of $55.50M.
Insulet Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 13 | 7 | 7 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $51.90M | $27.30M | $23.80M | $17.00M | $-5.20M | $-35.00M | $27.80M | $29.20M | $12.60M | $-25.00M | - | $-17.10M | $11.60M | $14.40M | $-2.10M | $4.97M | $852.00K |
| Avg Forecast | $113.52M | $98.77M | $80.19M | $73.43M | $89.89M | $77.84M | $62.67M | $56.56M | $76.00M | $57.51M | $41.69M | $32.54M | $48.29M | $29.80M | $19.41M | $29.58M | $22.08M | $11.23M | $16.58M | $26.90M | $23.14M | $18.31M | $9.94M | $5.35M | $-2.94M | $6.54M | $155.06K | $-406.80K | $8.03M | $2.55M |
| High Forecast | $115.91M | $100.86M | $81.89M | $74.98M | $91.79M | $79.48M | $63.99M | $67.30M | $86.23M | $57.78M | $41.72M | $39.05M | $58.38M | $40.98M | $19.82M | $35.50M | $26.50M | $11.23M | $16.58M | $32.27M | $23.14M | $18.31M | $9.94M | $5.35M | $-2.94M | $7.84M | $155.06K | $-406.80K | $8.03M | $2.55M |
| Low Forecast | $110.20M | $95.89M | $77.85M | $71.29M | $87.27M | $75.57M | $60.84M | $45.82M | $67.23M | $57.24M | $41.66M | $26.03M | $38.92M | $19.37M | $18.84M | $23.67M | $17.67M | $11.23M | $16.58M | $21.52M | $23.14M | $18.31M | $9.94M | $5.35M | $-2.94M | $5.23M | $155.06K | $-406.80K | $8.03M | $2.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.74% | 1.41% | 0.80% | 0.77% | -0.46% | -2.11% | 1.03% | 1.26% | 0.69% | -2.52% | - | 5.81% | 1.77% | 92.87% | 5.16% | 0.62% | 0.33% |
Insulet's average Quarter net income forecast for Dec 23 is $48.29M, with a range of $38.92M to $58.38M. PODD's average Quarter net income forecast represents a -6.96% decrease compared to the company's last Quarter net income of $51.90M (Sep 23).
Insulet SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 13 | 7 | 7 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $180.70M | $178.70M | $162.70M | $144.30M | $140.40M | $174.40M | $128.70M | $121.70M | $117.50M | $116.30M | $110.50M | $130.10M | $89.20M | $80.80M | $83.90M | $81.28M | $75.30M |
| Avg Forecast | $338.37M | $312.31M | $290.77M | $274.28M | $291.76M | $268.01M | $247.68M | $232.30M | $248.84M | $222.27M | $208.79M | $150.66M | $197.35M | $177.27M | $164.83M | $136.96M | $92.04M | $133.53M | $124.70M | $124.51M | $128.07M | $116.64M | $110.76M | $198.90M | $99.64M | $50.26M | $90.88M | $81.05M | $85.36M | $76.80M |
| High Forecast | $343.86M | $317.38M | $295.49M | $278.74M | $296.49M | $272.36M | $251.70M | $236.80M | $251.69M | $222.43M | $212.18M | $180.79M | $199.85M | $179.38M | $167.51M | $164.35M | $110.44M | $133.53M | $124.70M | $149.41M | $128.07M | $116.64M | $110.76M | $238.68M | $99.64M | $60.31M | $90.88M | $81.05M | $85.36M | $76.80M |
| Low Forecast | $330.77M | $305.30M | $284.24M | $268.13M | $285.21M | $261.99M | $242.12M | $226.88M | $243.28M | $222.12M | $204.10M | $120.53M | $195.26M | $173.76M | $161.13M | $109.57M | $73.63M | $133.53M | $124.70M | $99.61M | $128.07M | $116.64M | $110.76M | $159.12M | $99.64M | $40.21M | $90.88M | $81.05M | $85.36M | $76.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.08% | 1.19% | 1.57% | 1.05% | 1.40% | 1.03% | 0.95% | 1.01% | 1.05% | 0.56% | 1.31% | 1.77% | 0.89% | 1.04% | 0.95% | 0.98% |
Insulet's average Quarter SG&A projection for Dec 23 is $197.35M, based on 9 Wall Street analysts, with a range of $195.26M to $199.85M. The forecast indicates a 9.21% rise compared to PODD last annual SG&A of $180.70M (Sep 23).
Insulet EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 13 | 7 | 7 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.74 | $0.39 | $0.34 | $0.25 | $-0.07 | $-0.50 | $0.40 | $0.42 | $0.18 | $-0.37 | - | $-0.26 | $0.18 | $0.22 | $-0.03 | $0.08 | $0.01 |
| Avg Forecast | $1.54 | $1.34 | $1.08 | $0.99 | $1.22 | $1.05 | $0.85 | $0.76 | $1.03 | $0.78 | $0.56 | $0.40 | $0.65 | $0.40 | $0.26 | $0.11 | $0.22 | $0.15 | $0.22 | $0.23 | $0.31 | $0.25 | $0.13 | $0.07 | $-0.04 | $0.08 | - | $-0.01 | $0.11 | $0.03 |
| High Forecast | $1.57 | $1.36 | $1.11 | $1.01 | $1.24 | $1.07 | $0.87 | $0.91 | $1.17 | $0.78 | $0.56 | $0.40 | $0.79 | $0.55 | $0.27 | $0.11 | $0.22 | $0.15 | $0.22 | $0.23 | $0.31 | $0.25 | $0.13 | $0.07 | $-0.04 | $0.08 | - | $-0.01 | $0.11 | $0.03 |
| Low Forecast | $1.49 | $1.30 | $1.05 | $0.96 | $1.18 | $1.02 | $0.82 | $0.62 | $0.91 | $0.77 | $0.56 | $0.40 | $0.53 | $0.26 | $0.25 | $0.10 | $0.21 | $0.15 | $0.22 | $0.23 | $0.31 | $0.25 | $0.13 | $0.07 | $-0.04 | $0.08 | - | $-0.01 | $0.11 | $0.03 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.84% | 1.49% | 3.20% | 1.14% | -0.49% | -2.23% | 1.72% | 1.34% | 0.73% | -2.75% | - | 6.52% | 2.30% | 104.71% | 5.44% | 0.73% | 0.29% |
According to 9 Wall Street analysts, Insulet's projected average Quarter EPS for Dec 23 is $0.65, with a low estimate of $0.53 and a high estimate of $0.79. This represents a -11.76% decrease compared to PODD previous annual EPS of $0.74 (Sep 23).
Insulet Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TNDM | Tandem Diabetes Care | $27.34 | $79.05 | 189.14% | Buy |
| ALGN | Align | $223.69 | $421.00 | 88.21% | Buy |
| IART | Integra LifeSciences | $22.88 | $43.00 | 87.94% | Sell |
| TMDX | TransMedics Group | $80.48 | $126.75 | 57.49% | Buy |
| INMD | InMode | $18.01 | $27.50 | 52.69% | Hold |
| INSP | Inspire Medical Systems | $172.70 | $239.55 | 38.71% | Buy |
| NARI | Inari Medical | $50.56 | $66.11 | 30.76% | Buy |
| EW | Edwards Lifesciences | $67.76 | $88.04 | 29.93% | Buy |
| ABT | Abbott Laboratories | $115.90 | $126.45 | 9.10% | Buy |
| DXCM | DexCom | $75.88 | $81.36 | 7.22% | Buy |
| PODD | Insulet | $260.12 | $274.00 | 5.34% | Buy |
| MASI | Masimo | $161.07 | $161.83 | 0.47% | Buy |
| PEN | Penumbra | $237.84 | $224.85 | -5.46% | Buy |
| GKOS | Glaukos | $138.44 | $123.44 | -10.84% | Buy |
| SYK | Stryker | $390.08 | $317.96 | -18.49% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |